Ulf Jungnelius Md
Director of the Board and advisor for clinical and
Medicine
Isofol Medical
Sweden
Biography
Ulf’s past experience includes leading positions within oncology and clinical development at Celgene, Takeda, Pfizer and Eli Lilly. He has played key roles in the clinical development and regulatory approval process of blockbusters Gemzar® (gemcitabine) and Evista® (raloxifene). Key contributions to the clinical development of pharmaceuticals such as Alimta® (pemetrexed), Revlimid® (lenalidomide) and Vidaza® (azacitidine) are also a part of Ulf’s track record. In addition, he has led major Due Diligence processes which have resulted in multibillion dollar acquisitions, including Celgene’s acquisitions of Abraxis and Pharmion.
Research Interest
Ulf’s past experience includes leading positions within oncology and clinical development at Celgene, Takeda, Pfizer and Eli Lilly. He has played key roles in the clinical development and regulatory approval process of blockbusters Gemzar® (gemcitabine) and Evista® (raloxifene). Key contributions to the clinical development of pharmaceuticals such as Alimta® (pemetrexed), Revlimid® (lenalidomide) and Vidaza® (azacitidine) are also a part of Ulf’s track record. In addition, he has led major Due Diligence processes which have resulted in multibillion dollar acquisitions, including Celgene’s acquisitions of Abraxis and Pharmion.
